摘要
弥漫大B细胞淋巴瘤(DLBCL)是最常见的血液系统恶性肿瘤之一,常规采用利妥昔单抗联合环磷酰胺+阿霉素+长春新碱+泼尼松的治疗方案已将DLBCL的治愈率提高,但是不同患者的预后差异较大,目前预测预后的方法存在一定的局限性。^(18)F-氟脱氧葡萄糖(FDG)PET/CT已广泛应用于DLBCL的诊疗中,其代谢参数代谢肿瘤体积(MTV)是DLBCL预后强有力的预测因子,但如何将MTV更好地应用于临床尚存在一些争议,笔者就MTV在DLBCL预后预测中的研究进展进行综述。
Diffuse large B-cell lymphoma(DLBCL)is one of the most common hematologic malignancies,and the conventional application of Rituximab in combination with cyclophosphamide+adriamycin+vincristine+prednisone treatment regimen has increased the cure rate of DLBCL,but the prognosis varies widely among patients.The current methods for predicting prognosis have some limitations.^(18)F-fluorodeoxyglucose(FDG)PET/CT has been widely used in the diagnosis and treatment of DLBCL,and its metabolic parameter metabolic tumor volume(MTV)is a strong predictor.However,there are still some controversies on how to better apply MTV in clinical practice.This paper reviews the research progress of MTV in predicting the prognosis of DLBCL.
作者
杨帅
沈秋怡
付鹏
赵长久
Yang Shuai;Shen Qiuyi;Fu Peng;Zhao Changjiu(Department of Nuclear Medicine,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)
出处
《国际放射医学核医学杂志》
2022年第10期624-628,共5页
International Journal of Radiation Medicine and Nuclear Medicine
